Back to today’s briefing

Story perspectives

GeoVax Faces Losses, Analysts Still Back 'Buy' Rating

4/19/2025

34 5

Summary

Story summary

Noble Financial has revised its Q2 2025 earnings forecast for GeoVax Labs (NASDAQ:GOVX) to a loss of $0.44 per share, bringing the full-year estimate to $4.49 per share. Despite recent stock struggles, five analysts still endorse a “buy” rating, with a hopeful target price of $12.90, as GeoVax continues its mission to combat infectious diseases and cancers.

1 of 1

Story summary

Noble Financial has revised its Q2 2025 earnings forecast for GeoVax Labs (NASDAQ:GOVX) to a loss of $0.44 per share, bringing the full-year estimate to $4.49 per share. Despite recent stock struggles, five analysts still endorse a “buy” rating, with a hopeful target price of $12.90, as GeoVax continues its mission to combat infectious diseases and cancers.